Overview

• Biotech firm reported Q4 2025 net loss of $102.5 mln, increased from last year

• Company maintains strong cash position with $901 mln, funding operations into 2028

• Bezuclastinib NDA submissions on track for 2026, including AdvSM and GIST indications

Outlook

• Cogent plans to submit APEX NDA for bezuclastinib in 1H 2026

• Company aims to launch bezuclastinib in second half of 2026

• Cogent expects cash runway to support operations into 2028

Result Drivers

• NDA SUBMISSIONS - Cogent submitted SUMMIT NDA for bezuclastinib in NonAdvSM and initiated PEAK NDA for GIST under RTOR program

• CLINICAL TRIAL PROGRESS - Bezuclastinib showed clinical benefits in SUMMIT and APEX trials, with significant symptom improvements and high response rates

• FINANCIAL POSITION - Cogent maintains strong cash reserves of $901 mln, supporting operations into 2028

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Cogent Biosciences Inc is $50.50, about 38.2% above its February 13 closing price of $36.53

Press Release: ID:nGNX28xgdW

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)